PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer.

Abstract An ever increasing number of drugs directed as epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) bring a new revolution for non-small cell lung cancer (NSCLC) therapy, and many large scales of studies show that only people with EGFR-sensitive mutation can benefit from these drugs. The main method of EGFR mutation detection is to analyze the DNA sequence of EGFR, which can be the lung cancer tissue, pleural fluid tumor cells, circulating tumor cells and peripheral blood free DNA obtained by surgery or puncture, the biggest drawback is that the heterogeneity of EGFR mutation cannot be analyzed. However, with the development of molecular imaging, the development of EGFR-targeted molecular probes based on positron emission computed tomography-computed tomography (PET-CT) has made it possible to reveal the EGFR mutations in lung cancer tissues in vivo, and can detect the heterogeneity of EGFR mutations. This article reviews all the results and progress of molecular probes targeting EGFR mutations.
PMID
Related Publications

Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Authors

Mayor MeshTerms

Mutation

Keywords
Journal Title zhongguo fei ai za zhi = chinese journal of lung cancer
Publication Year Start




PMID- 28641700
OWN - NLM
STAT- MEDLINE
DA  - 20170623
DCOM- 20170630
LR  - 20170630
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Linking)
VI  - 20
IP  - 6
DP  - 2017 Jun 20
TI  - [Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung
      Cancer].
PG  - 415-420
LID - 10.3779/j.issn.1009-3419.2017.06.08 [doi]
AB  - An ever increasing number of drugs directed as epidermal growth factor receptor
      tyrosine kinase inhibitor (EGFR-TKI) bring a new revolution for non-small cell
      lung cancer (NSCLC) therapy, and many large scales of studies show that only
      people with EGFR-sensitive mutation can benefit from these drugs. The main method
      of EGFR mutation detection is to analyze the DNA sequence of EGFR, which can be
      the lung cancer tissue, pleural fluid tumor cells, circulating tumor cells and
      peripheral blood free DNA obtained by surgery or puncture, the biggest drawback
      is that the heterogeneity of EGFR mutation cannot be analyzed. However, with the 
      development of molecular imaging, the development of EGFR-targeted molecular
      probes based on positron emission computed tomography-computed tomography
      (PET-CT) has made it possible to reveal the EGFR mutations in lung cancer tissues
      in vivo, and can detect the heterogeneity of EGFR mutations. This article reviews
      all the results and progress of molecular probes targeting EGFR mutations.
FAU - Luo, Danjing
AU  - Luo D
AD  - Department of Oncology, The Second Xiangya Hospital, Center South University,
      Changsha 410011, China.
FAU - Ma, Jin'an
AU  - Ma J
AD  - Department of Oncology, The Second Xiangya Hospital, Center South University,
      Changsha 410011, China.
FAU - Zhang, Jinming
AU  - Zhang J
AD  - Department of Nuclear Medicine, The PLA General Hospital, Beijing 100853, China.
FAU - Zhao, Yanzhong
AU  - Zhao Y
AD  - The Medical Experimental Center, the Third Xiangya Hospital, Central South
      University, Changsha 410013, China.
LA  - chi
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*diagnostic imaging/enzymology/*genetics
MH  - Humans
MH  - Lung Neoplasms/*diagnostic imaging/enzymology/*genetics
MH  - Molecular Imaging/*methods
MH  - *Mutation
MH  - Receptor, Epidermal Growth Factor/*genetics
EDAT- 2017/06/24 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/24 06:00
AID - 10.3779/j.issn.1009-3419.2017.06.08 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):415-420. doi:
      10.3779/j.issn.1009-3419.2017.06.08.